论文部分内容阅读
目的研究在非小细胞肺癌组织中转化生长因子(TGF)-β1信号抑制子Smad7表达水平的变化,探讨Smad7在肺癌发生中的作用。方法收集46例临床肺鳞癌、腺癌标本,用免疫组织化学方法检测肺癌及癌旁组织中Smad7的表达丰度,比较表达差异,并取肿瘤组织检测为阳性的12例鳞癌病例标本,分别提取其癌组织及癌旁组织总蛋白,用Westernblot进行验证。结果肺癌组织中Smad7表达总阳性率为44%(20/46),显著高于癌旁组织17%(8/46()χ2=7.91,P<0.01);其中,鳞癌和腺癌癌组织中Smad7的阳性率分别为60%(12/20)和31%(8/26),癌旁组织中Smad7的阳性率分别为25%(5/20)和12%(3/26)。肺鳞癌组织中Smad7的表达高于癌旁组织(χ2=5.01,P<0.05)。Westernblot验证结果表明,免疫组织化学检测阳性的12例标本癌组织Smad7Westermblot检测均为阳性,其中有7例癌组织Smad7表达高于癌旁组织,进一步验证了Smad7蛋白在肺鳞癌中表达增高。结论Smad7的过表达同肺鳞癌的发生相关。
Objective To investigate the expression of Smad7, a transforming growth factor (TGF) -β1 signaling inhibitor, in non-small cell lung cancer (NSCLC) and to explore the role of Smad7 in lung carcinogenesis. Methods Forty - six clinical specimens of squamous cell carcinoma and adenocarcinoma were collected. The expression of Smad7 was detected by immunohistochemical method in lung cancer tissues and paracancerous tissues. The expression of Smad7 was compared between the two groups. Twelve specimens of squamous cell carcinoma with positive tumor tissues were collected. The total protein in cancer tissues and adjacent tissues was extracted and verified by Western blot. Results The positive rate of Smad7 in lung cancer was 44% (20/46), significantly higher than that in para-cancerous tissues (8/46 (2) = 7.91, P <0.01) The positive rates of Smad7 were 60% (12/20) and 31% (8/26) in the paracancerous tissues and 25% (5/20) and 12% (3/26) respectively in the adjacent tissues. The expression of Smad7 in squamous cell carcinoma tissues was higher than that in adjacent tissues (χ2 = 5.01, P <0.05). The result of Western blot showed that the Smad7Westermblot was positive in 12 specimens of which the immunohistochemistry was positive, and the expression of Smad7 in 7 specimens was higher than that in paracancerous tissues, further confirming the increase of Smad7 protein in squamous cell lung cancer. Conclusion The overexpression of Smad7 is associated with the occurrence of squamous cell carcinoma of the lung.